1. Home
  2. TECH vs ROIV Comparison

TECH vs ROIV Comparison

Compare TECH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

N/A

Current Price

$57.01

Market Cap

9.5B

Sector

Health Care

ML Signal

N/A

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

N/A

Current Price

$22.87

Market Cap

14.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TECH
ROIV
Founded
1976
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
14.1B
IPO Year
1989
N/A

Fundamental Metrics

Financial Performance
Metric
TECH
ROIV
Price
$57.01
$22.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
8
Target Price
$71.23
$24.31
AVG Volume (30 Days)
1.8M
7.4M
Earning Date
02-04-2026
11-10-2025
Dividend Yield
0.56%
N/A
EPS Growth
N/A
N/A
EPS
0.49
N/A
Revenue
$1,216,732,000.00
$20,329,000.00
Revenue This Year
$2.33
N/A
Revenue Next Year
$7.05
$376.94
P/E Ratio
$118.01
N/A
Revenue Growth
3.85
N/A
52 Week Low
$46.01
$8.73
52 Week High
$79.28
$23.23

Technical Indicators

Market Signals
Indicator
TECH
ROIV
Relative Strength Index (RSI) 38.12 71.54
Support Level $56.59 $20.14
Resistance Level $61.20 $21.48
Average True Range (ATR) 1.97 0.79
MACD -0.65 0.14
Stochastic Oscillator 4.84 85.33

Price Performance

Historical Comparison
TECH
ROIV

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: